Abstract
The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC(50)=169, 85, 21 nM) and 42 (SERT, NET, DAT IC(50)=34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Amines / chemical synthesis*
-
Amines / chemistry
-
Amines / pharmacology
-
Animals
-
Antidepressive Agents / chemical synthesis
-
Antidepressive Agents / chemistry
-
Antidepressive Agents / pharmacology
-
Cyclization
-
Dopamine Uptake Inhibitors* / chemical synthesis
-
Dopamine Uptake Inhibitors* / chemistry
-
Dopamine Uptake Inhibitors* / pharmacology
-
Drug Design*
-
Inhibitory Concentration 50
-
Methane / chemical synthesis*
-
Methane / chemistry
-
Methane / pharmacology
-
Mice
-
Molecular Structure
-
Norepinephrine* / chemical synthesis
-
Norepinephrine* / chemistry
-
Norepinephrine* / pharmacology
-
Rats
-
Serotonin* / chemical synthesis
-
Serotonin* / chemistry
-
Serotonin* / pharmacology
-
Stereoisomerism
Substances
-
Amines
-
Antidepressive Agents
-
Dopamine Uptake Inhibitors
-
Serotonin
-
Methane
-
Norepinephrine